Brentview Investment Management LLC Buys New Stake in Novo Nordisk A/S (NYSE:NVO)

Brentview Investment Management LLC bought a new stake in shares of Novo Nordisk A/S (NYSE:NVO) during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 2,334 shares of the company’s stock, valued at approximately $201,000.

Several other hedge funds and other institutional investors have also made changes to their positions in NVO. AQR Capital Management LLC lifted its holdings in shares of Novo Nordisk A/S by 110.5% during the 2nd quarter. AQR Capital Management LLC now owns 17,164 shares of the company’s stock valued at $2,450,000 after acquiring an additional 9,012 shares in the last quarter. Healthcare of Ontario Pension Plan Trust Fund lifted its holdings in Novo Nordisk A/S by 45.8% in the 2nd quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 23,664 shares of the company’s stock worth $3,378,000 after buying an additional 7,430 shares in the last quarter. WealthBridge Capital Management LLC lifted its holdings in Novo Nordisk A/S by 8.4% in the 3rd quarter. WealthBridge Capital Management LLC now owns 6,780 shares of the company’s stock worth $807,000 after buying an additional 525 shares in the last quarter. Azzad Asset Management Inc. ADV lifted its holdings in Novo Nordisk A/S by 55.9% in the 3rd quarter. Azzad Asset Management Inc. ADV now owns 41,107 shares of the company’s stock worth $4,895,000 after buying an additional 14,731 shares in the last quarter. Finally, Parisi Gray Wealth Management lifted its holdings in Novo Nordisk A/S by 19.6% in the 3rd quarter. Parisi Gray Wealth Management now owns 3,990 shares of the company’s stock worth $475,000 after buying an additional 653 shares in the last quarter. Institutional investors and hedge funds own 11.54% of the company’s stock.

Wall Street Analyst Weigh In

NVO has been the topic of a number of recent analyst reports. UBS Group upgraded shares of Novo Nordisk A/S from a “sell” rating to a “buy” rating in a report on Wednesday, January 8th. BNP Paribas upgraded shares of Novo Nordisk A/S to a “strong-buy” rating in a report on Monday, December 2nd. Cantor Fitzgerald reiterated an “overweight” rating and issued a $160.00 price objective on shares of Novo Nordisk A/S in a report on Wednesday, November 6th. Sanford C. Bernstein upgraded shares of Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research note on Monday, January 6th. Finally, StockNews.com lowered shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research note on Sunday, December 29th. One equities research analyst has rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $145.25.

Novo Nordisk A/S Stock Performance

Shares of Novo Nordisk A/S stock opened at $84.36 on Monday. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.75 and a current ratio of 0.94. Novo Nordisk A/S has a 1 year low of $78.17 and a 1 year high of $148.15. The firm’s 50-day simple moving average is $93.56 and its 200-day simple moving average is $113.03. The firm has a market cap of $378.56 billion, a PE ratio of 27.30, a price-to-earnings-growth ratio of 0.93 and a beta of 0.45.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.